DAX
18.163,52 -90,66 (-0,50%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dow Jones 30
39.150,33 +15,57 (+0,04%) Gold
2.334,70 -34,30 (-1,45%) EUR/USD
1,0697 -0,0009 (-0,09%) Bitcoin EUR
60.263,55 +158,10 (+0,26%)
Novavax, Inc. (NVAX)
Nachbörse:
Novavax, Inc.
700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.543
Beschreibung
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Corporate Governance
Novavax, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 5. Die grundlegenden Scores sind Audit: 7, Vorstand: 3, Shareholderrechte: 5, Kompensation: 6.
